Philippe Ledru - Jan 19, 2023 Form 4 Insider Report for Aptose Biosciences Inc. (APTO)

Role
Chief Commercial Officer
Signature
/s/ Fletcher Payne as attorney-in-fact for Philippe Ledru
Stock symbol
APTO
Transactions as of
Jan 19, 2023
Transactions value $
$0
Form type
4
Date filed
1/23/2023, 06:55 PM
Previous filing
Apr 14, 2022
Next filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APTO Common Shares Award $0 +100K +20000% $0.00 101K Jan 19, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APTO Employee Stock Option (Right to Buy) Award $0 +200K $0.00 200K Jan 19, 2023 Common Shares 200K $0.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fifty percent (50%) of the options vest on January 19, 2024; the remaining fifty percent (50%) vest as follows: One-third (1/3) on January 19, 2025; one-third (1/3) on January 19, 2026; and one-third (1/3) on January 19, 2027.